Modulation of Protective Immunity, Eosinophilia, and Cytokine Responses by Selective Mutagenesis of a Recombinant G Protein Vaccine against Respiratory Syncytial Virus

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Virology

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.79.7.4527-4532.2005PMID 15767454PMCID PMC1061523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biology of Natural Killer Cells

  2008cited by this paper
• Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV

  2004cited by this paper
• Identification of a Common HLA-DP4-Restricted T-Cell Epitope in the Conserved Region of the Respiratory Syncytial Virus G Protein

  2004cited by this paper
• IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge 1

  2003cited by this paper
• A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV).

  2003cited by this paper
• Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P

  2003cited by this paper
• Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans.

  2002cited by this paper
• A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease

  2002cited by this paper
• Respiratory syncytial virus immunobiology and pathogenesis.

  2002cited by this paper
• Differential Histopathology and Chemokine Gene Expression in Lung Tissues following Respiratory Syncytial Virus (RSV) Challenge of Formalin-Inactivated RSV- or BBG2Na-Immunized Mice

  2001cited by this paper
• Immunomodulators and delivery systems for vaccination by mucosal routes.

  2001cited by this paper
• Immunopathogenesis of vaccine-enhanced RSV disease.

  2001cited by this paper
• The Attachment (G) Glycoprotein of Respiratory Syncytial Virus Contains a Single Immunodominant Epitope That Elicits Both Th1 and Th2 CD4+ T Cell Responses1

  2000influential reference
• Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.

  2000cited by this paper
• Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent

  1999cited by this paper
• Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.

  1999cited by this paper
• Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism

  1999cited by this paper
• Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia

  1998cited by this paper
• Atypical Pulmonary Eosinophilia Is Mediated by a Specific Amino Acid Sequence of the Attachment (G) Protein of Respiratory Syncytial Virus

  1998cited by this paper
• Intracellular IFN-γ expression in natural killer cells precedes lung CD8MT cell recruitment during respiratory syncytial virus infection

  1998cited by this paper
• Requirement for IL-13 independently of IL-4 in experimental asthma

  1998cited by this paper
• Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection.

  1998cited by this paper
• Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.

  1998cited by this paper
• Requirement for IL-13 independently of IL-4 in experimental asthma.

  1998cited by this paper
• Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine.

  1997cited by this paper
• Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection

  1997cited by this paper
• Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus

  1996cited by this paper
• Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern

  1996cited by this paper
• Vaccines and cytokine-mediated pathology in RSV infection.

  1994cited by this paper
• The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.

  1994cited by this paper
• Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10

  1994cited by this paper
• Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

  1993cited by this paper
• Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.

  1992cited by this paper
• Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life.

  1991cited by this paper
• Viral respiratory tract infection and exacerbations of asthma in adult patients.

  1988cited by this paper
• Risk of primary infection and reinfection with respiratory syncytial virus.

  1986cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969cited by this paper
• Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

  1969cited by this paper
• Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

  1969cited by this paper
• An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

  1969cited by this paper

• Deciphering the heparin-binding domain of RSV G protein in host-pathogen interactions

  2025cites this paper
• TLR7 promotes chronic airway disease in RSV-infected mice

  2023cites this paper
• Prospects for defined epitope vaccines for respiratory syncytial virus.

  2010cites this paper
• Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice

  2010cites this paper
• Respiratory Syncytial Virus (RSV): Characteristics of Infection and the Role of Immune Response in the Evolution of Disease

  2009cites this paper
• Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.

  2009cites this paper
• Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis.

  2009cites this paper
• Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.

  2007cites this paper
• Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV)

  2006cites this paper
• Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy—a review

  2006cites this paper